Stein discusses the results of a groundbreaking open-label extension, which indicates the efficacy and safety of this investigative oral PCSK9 inhibitor.
Evan Stein, MD, PhD
Advertisement
Evan Stein, MD, PhD, is the COO and CSO of LIB Therapeutics.
Articles by Evan Stein, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
2
Evaluating Clinical and Real-World Evidence in Hypercortisolism
3
Management Strategies for Hypercortisolism
4
Interstitial Lung Abnormalities: Recognition, Risk Stratification, and When to Act
5